ACTRIMS 2020: Post-Conference Perspectives
Investigators caution health care providers to consider specific risks of severe COVID-19 infection before initiating this therapy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
2
AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome
3
Open Label Extension Confirms Cenobamate's Efficacy in Asian Populations
4
Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease
5
